REVIEW ARTICLE  ON SUSTAINED RELEASE DELIVERY SYSTEM OF ANTI-PLATELET DRUGS

Shivesh Prasad Sinha; Dr.Manish Jaimini

doi:10.61280/tjpls.v9i5.99

Shivesh Prasad Sinha Department of Pharmacy,Mahrishi Arvind University, Jaipur
Dr.Manish Jaimini Department of Pharmacy, Mahrishi Arvind University, Jaipur

DOI: https://doi.org/10.61280/tjpls.v9i5.99

Keywords:

Sustained Release, Antiplatelet medications antiplatelet therapy, oral drug delivery system

Abstract

Antiplatelet medications currently on the market interfere with one or more phases in the platelet release and aggregation process, leading to a meaningful decrease in thrombosis risk that cannot be separated from an elevated risk of bleeding. Understanding that under physiological conditions, 1011 platelets are created daily-a quantity that can rise up to 10-fold during times of greater need—is crucial when thinking about antiplatelet medications.

Downloads

Download data is not yet available.

References

Modi Foram P, Patel Priyal R: Formulation, optimization & evaluation of fixed dose combination moisture barrier film coated bilayer tablet of Artesunate & Amodiaquine Hydrochloride: International Journal of Pharm Tech Research 2011:3(4): 2124-2134.

Durga Prasad Pattanayak, Subas H C Dinda; Bilayer tablet formulation of metformin hydrochloride and glimepiride: A novel approach to improve therapeutic efficacy; International journal of drug discovery and herbal research 1(1): Jan-Mar: (2011); 1-4.

Ajit Kulkarni, Manish Bhatia: Development and evaluation of regioselective bilayer floating tablets of atenolol and lovastatin for biphasic release profile: Iranian Journal of Pharmaceutical Research;2009: 1(8): 1-5

M Muthukumaran, D Dhachinamoorthi and K B Chandra Sekhar Fabrication and evaluation of sustained release mucoadhesive bilayer tablets containing nifedipine: Der Pharmacia Sinica, 2012:3 (3):367-376.

R Z Mujoriya, Venkateshvarlu, D C Singh, V A Gupta, A Bisen, and A B Bondre: Formulation Development and Evaluation of Metoprolol Succinate Er and Amlodipine Besilate Bilayer Tablet: Research J. Pharm. and Tech. 3(4): Oct.-Dec. 2010: 1-4

Akash Yadav, Dinesh Kumar Jain; Formulation development and in vitro characterization of bilayer and floating-bioadhesive tablets of propranolol hydrochloride; Asian Journal of Pharmacy & Life Science; 1 (1), Jan-Mar, 2011: 2-12

Jain Jitendra, Bhavna H. marya, Mittal R Patani, Mandevpatel; Formulation and Evaluation of Indomethacin Bilayer Sustained Release Tablets; April-June 2011; 3(2):1132- 1138.

Rahman Z, Ali M, Khar RK. Design and evaluation of bilayer floating tablets of captopril. Acta Pharm.2006; 56:49-57

Abdul Althaf S, Sailaja P B, Ashwin Kumar M: Formulation, Evaluation and Mathematical Modelling of Clopidogrel Bisulphate & Aspirin Immediate Release Bilayer Tablets; Pharmaceut Anal Acta 3: 194. 3(9)

Fake, A. L. (2018). Antiplatelet and anticoagulant therapy in patients with acute coronary syndromes and atrial fibrillation (Thesis, Doctor of Philosophy). University of Otago. Retrieved from http://hdl.handle.net/10523/8105

Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014 Oct;34(10):1077-90. doi: 10.1002/phar.1477.

Teng, R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet 54, 1125–1138 (2015). https://doi.org/10.1007/s40262-015-0290-2

Fuller R, Chavez B. Ticagrelor (brilinta), an antiplatelet drug for acute coronary syndrome. P T. 2012 Oct;37(10):562-8. PMID: 23115464; PMCID: PMC3474441.

Hoshino H, Toyoda K, Omae K, Ishida N, Uchiyama S, Kimura K, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, Matsumoto M, Tominaga T, Tomimoto H, Terayama Y, Yasuda S, Yamaguchi T; CSPS.com Trial Investigators. Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial. Stroke. 2021 Nov;52(11):3430-3439. doi: 10.1161/STROKEAHA.121.034378.

Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005 Dec 15;6(4):3-11. doi: 10.1016/j.atherosclerosissup.2005.09.002.

Elam, M. B.; Heckman, J.; Crouse, J. R.; Hunninghake, D. B.; Herd, J. A.; Davidson, M.; Gordon, I. L.; Bortey, E. B.; Forbes, W. P. (1998). Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication. Arteriosclerosis, Thrombosis, and Vascular Biology, 18(12), 1942–1947. doi:10.1161/01.atv.18.12.1942

Sorkin, E.M., Markham, A. Cilostazol. Drugs & Aging 14, 63–71 (1999). https://doi.org/10.2165/00002512-199914010-00005.

Kim YH, Ghim JL, Jung JA, Cho SH, Choe S, Choi HY, et al. Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers. Drug Des DevelTher2015;9:3571-3577. doi: 10.2147/DDDT.S86845

Kim HS, Kim GY, Yeo CW, Oh MK, Ghim JL, Shon JH, et al. The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects. Br J Clin Pharmacol2014;77:821-830. doi: 10.1111/bcp.12236.

Shin KH, Yoon G, Yoon IS, Park JW. Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants. J Pharm Pharmacol. 2014;66:961-974. doi: 10.1111/jphp.12227.

Dawson DL, Cutler BS, Meissner MH, Strandness DE, Jr. Cilostazol has beneficial effects in treatment of intermittent claudication. Results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98:678- 686.

Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J med Med2000;109:523-530.

Horie N, Kaminogo M, Izumo T, Hayashi K, Tsujino A, Nagata I. Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. Neurol Res 2015;37:619-623. doi: 10.1179/1743132815Y.0000000021.

Chi YW, Lavie CJ, Milani RV, White CJ. Safety and efficacy of cilostazol in the management of intermittent claudication. Vasc Health Risk Manag. 2008;4(6):1197-203. doi: 10.2147/vhrm. s3160. PMID: 19337533; PMCID: PMC2663440.

Liu JS, Chuang TJ, Chen JH, Lee CH, Hsieh CH, Lin TK, et al. Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. Endocrine 2015; 49:703-710. doi: 10.1007/s12020-015-0545-6.